Vivos Therapeutics (VVOS) Projected to Post Quarterly Earnings on Tuesday

Vivos Therapeutics (NASDAQ:VVOS) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $3.63 million for the quarter.

Vivos Therapeutics (NASDAQ:VVOS) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.15. The company had revenue of $3.70 million during the quarter, compared to the consensus estimate of $3.89 million. Vivos Therapeutics had a negative net margin of 86.19% and a negative return on equity of 335.04%. On average, analysts expect Vivos Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vivos Therapeutics Stock Up 6.0 %

VVOS opened at $3.01 on Friday. The business’s fifty day simple moving average is $2.84 and its 200 day simple moving average is $3.55. Vivos Therapeutics has a 52 week low of $1.91 and a 52 week high of $6.28. The stock has a market cap of $17.73 million, a PE ratio of -0.53 and a beta of 7.31.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on VVOS. Alliance Global Partners reissued a “buy” rating on shares of Vivos Therapeutics in a report on Tuesday, April 1st. Ascendiant Capital Markets decreased their price target on shares of Vivos Therapeutics from $6.60 to $6.20 and set a “buy” rating on the stock in a research note on Tuesday, April 15th.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.